Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Pharma Sessions

Pharma Sessions artwork

Bursting the Med Affairs Bubble with Dr. Samin Saeed, VP Early Medical Pipeline at GSK

Dec 3, 202430 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Bursting the Medical Affairs Bubble: A Conversation on Cross-Functional Collaboration In this episode of Pharma Sessions, host Jonathan Kaskey talks with Dr. Samin Saeed, a pharmaceutical medical affairs leader with 17 years of industry experience currently at GSK. They discuss the need for medical affairs to move beyond speaking only to themselves and to engage more openly with other functions within pharmaceutical organizations. Dr. Saeed advocates for a collaborative approach and shares h... Pharma Sessions is hosted by Jonathan Kaskey Follow along on LinkedIn: https://www.linkedin.com/in/jonkaskey/ Or join the Pharma Sessions Substack: www.pharmasessions.substack.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_00If you're w operating in a bubble, it's about your views and your ideas, and it's a great plan. And I don't how dare you challenge silly commercial people who don't know what you're talking about, which is not the right way to approach it.

SPEAKER_01Hello, hello, and welcome to Pharma Sessions, the podcast where Metafares comes to learn from each other. I'm your host, Jonathan Kaskey. Good morning. How are you today?

SPEAKER_00I'm great. How are you?

SPEAKER_01I'm doing very well. Do you want to give the audience a quick introduction to who you are?

SPEAKER_00Yeah, I'd love to. So for those of you that don't know me, my name is Dr. Samin Said. I'm a pharmaceutical medical affairs leader. I've been in the industry now 17 years. I've worked for a number of different companies, currently at GSK in a global medical affairs role.

SPEAKER_01We met over LinkedIn, and I think what prompted that was I saw a post that you posted, for lack of a better term, about bursting the Metafairs bubble. And to be honest, I felt a bit attacked because my podcast is all about Metapheres for Metafares. So tell me, why is this venture a bad idea and why have I been doing it wrong for so many years?

SPEAKER_00So no, I think what it is, and I'm not saying that anyone's saying anything wrong, and I understand why we are where we are, but I think over the last few years, I'm certainly observing that there's a lot of content, particularly in the social media space and particularly on LinkedIn, where and various meetings where it's all sort of medical affairs driven for medical affairs, and we're we're we're talking to each other about how great we are and the value we're adding and all of the things that we need to do to prove our value. And sometimes I feel that we are doing this almost in this bubble and forgetting that we are actually a small piece of a much broader organization in a huge industry.

SPEAKER_00Clearly, there have been many opinion papers written about the value of medical affairs in the future. McKinsey obviously did the one for 2025, they've got their 2030 vision, and various other consultancies have followed suit. Um but I think the view I have is that it shouldn't just be medical telling medical how great we are. If we are really adding the value that we believe we are, then there should be a commercial edge that we're bringing to organizations and it should be discussed outside of medical, really.

SPEAKER_00And I think that's what I'm not seeing, which is why it prompted me to write that post. And also internally, when big organizations that I've worked in, it's a similar feel. You often feel that medical are sat there trying to defend themselves and we're really important, we're the third pillar, we're this, we're that. And actually, there is part of me that goes about how are we showing up? How are we adding that value? And it isn't just about us saying it, it's about having those conversations at a very senior leadership level as to what we're accountable for.

SPEAKER_01Yeah. And I think so. My perspective on this, I've been touching Metafairs from the outside, from a vendor perspective, for say 10 years or so, right? And when I first started, I was very interested in there's a lot of content about how do we communicate the value of Metafairs and how do we go beyond the number of meetings that the MSLs are having. And I don't want to say it's disheartening, but you still see those same papers and those same posts. And what I'm wondering is after all of that, how much of it do you think is really does come down to company by company discussions with your particular set of senior leaderships about what are you in particular looking to see for Metafairs versus something that we can try to apply more globally?

SPEAKER_00Yeah, and I think that's exactly the question, right? I think those organizations that really understand how to utilize the functions and the talent they've got and the people and the how they want their organization to look, you can have proper conversations with them about what is it that they're expecting from each of their departments, including medical affairs. Let's be really clear about what medical affairs are accountable for, what they are, what we're holding their feet to the fire for. And therefore, how do we measure that and what are we looking for? You will still get some organizations that don't see that and still see medical affairs as just a glorified compliance function who are there to sign off content and get their MSLs out there as more experienced, rep-like people.

SPEAKER_00And I just don't think in those sorts of organizations you're going to get a lot of traction. You could have some senior medical person who's able to talk at a high level as to the value that can be added, but it becomes an organizational decision at some point. And, you know, I just feel sometimes as medical affairs, we're sat here being done onto and we're almost it's a bit of this victim mindset that I want us to move away from and realize actually at the end of the day, it's an organizational choice how they want to use their departments.

SPEAKER_01Yeah, it's interesting. I think that this idea of silos and whatnot, it's not really specific to a Metafairs problem. It's something that Pharma is doing in general. Like, for example, I was just last week at this symposium called GPROS, which is all about labeling. And there were some people in the labeling regulatory space talking about why you actually do need to involve commercial way earlier when you're starting to think about your label, because that ends up being like the thing that goes out to the market and you need to design your clinical. So it's with the end in mind, right?

SPEAKER_01So that struck me as super familiar to what we're hearing with Metafairs. So it's not for the Metafairs people out there, it's not you, right? These are there are some industry forces that are or tailwinds that you're facing. But what if we could get maybe a little bit more specific, one of the things we talked about in the lead up to this was the idea of setting up a culture of collaboration. And I'm just wondering if there's anything you can share about where you've seen that done well, either by yourself, by others that you've come across to give some people some maybe something a little more tangible to think about.

SPEAKER_00Yeah. And I think having said all of the things that we've just said, I'm not saying that it's impossible or it's not possible to influence. Of course, that's that's within all of our gifts. And I think one of the things that we have to recognize in whatever function we're in is the people that we're working with and we're collaborating with, what are they trying to achieve? Ultimately, I think as a function, we have to understand that we are a key part in the process of commercialization. And sometimes we find that an ugly word, but it's true.

SPEAKER_00And if you frame commercialization as the process of getting medicines or innovations to patients at scale and pace, then of course medical affairs has a role in that. And I think if you understand that's you have a role in that, then it's about actually what is it that we are trying to do as an organization? Who are the players? What are their roles and how do I fit in? And I think having that sort of you start off by having that curiosity, right? You go into an organization, and certainly that's something I've seen work for myself and for others. You go in, you really try to understand how is this, what the organization is trying to do, and what molecules have they got, where are they in their processes when it comes to launch or pipeline or whatever, who have they got in place, what are they trying to do?

SPEAKER_00And then think about actually where is it that my role sits and how can I add value? And then having those conversations, building the trust, building the relationships with your cross-functional partners and peers, um, and and then taking it from there. Because I think having those open, honest conversations, you're going to get much further. But it does start from understanding their perspective first and not coming in with a sort of I'm medical affairs and this is my job. It does come with going in, understanding the layout, the layer of the land, and then really figuring out the value we can add and articulating it.

SPEAKER_00And it's not too dissimilar to a process I'm going through at this moment. We've got a great medical affairs team. We're working in the early space, and there's a lot of value being added. Sometimes it's about understanding what the various players want and how do we then showcase what we can do and articulate that.

SPEAKER_01Yeah. So there's a lot there. So let me just ask a couple of questions on that. I really like this idea of changing the mindset around how you engage with commercial, right? Where what you said, I think, was commercial is getting medicines to patients at pace and at scale. And that's very different than maximizing shareholder value or increasing revenues. But that's ultimately what it is, right? You're make working on medicines and they don't do any good if they're sitting on the shelf. Right? They need to get into people's bodies. So that's how I guess my question is how, and then what you described was almost like take a step back and do some strategic work and some planning and some mapping of where you can bring value to the organization and work within your particular organization.

SPEAKER_01Do companies typically give space to take that time and and do that work, or is that something you have to carve out for yourself?

SPEAKER_00I think again, it varies. It depends on the, you know, so I've certainly worked in organizations where there was the empowerment was given. And the expectation, to be fair, was actually you're part of this machine. Go forth and figure out how your team are gonna add value to what we're trying to do here. But then there are times where you are literally just, I think I did a LinkedIn post where people are just sort of drowning with stuff, and it's then hard to know of where I can pop my head up and have that strategic lens. But then that does become uh if you're a senior medical leader, then that is on you to try and make that space to make it happen.

SPEAKER_00And I'm not it's not easy. I'm not gonna pretend, oh yeah, it's just easy, just do this and you're done. It does take a bit of bravery. Um, and you might not be, you might rub people up the wrong way, but ultimately, if your aim is to improve what you believe is right for the organization and you can um speak to the people around you and they see that too, um, then that should help you on your way. But you're right, you have to create that space first in some places, and it's that's not always easy.

SPEAKER_00So I'm not going to pretend it is, and my heart goes out to people who are trying. Um, and it's probably a controversial thing to say. Sometimes organizations aren't ready for the future, they're the current, they're not ready for the type of medical affairs that some of us believe we can add, and maybe that's not the right place for you. Maybe you need to be in an organization where they see the value and you are then empowered to go forth and deliver. But there's no one size fits all. Every organization has different approaches, different cultures, um, different ways of working.

SPEAKER_00So I think it's really up to you as an individual as to how you can either try and influence, um, figure out a path, and if not, then figure out other options.

SPEAKER_01100%. Because that's just another form of empowerment that you're talking about. And from personal experience, before I was at the company that I'm at now, I was at a different place for six years, loved it, tried something new, didn't like the organization at all, didn't like the culture. I won't say who it is. They're not on my LinkedIn. It wasn't a meaningful experience for me.

SPEAKER_00Oh, do you build a no, I won't. You're gonna be careful if you say something new to what you say. But yeah, no, you're right.

SPEAKER_01It's but other people were very happy there. It's not necessarily that it was bad, it just wasn't right for me. And that's okay. We move on. But I think so in your own career, did you find you had to were you taking those that sort of kind of strategic view and those making those strategic efforts before you were in leadership positions? Or were you working towards that with this idea of, hey, once I'm in once I'm calling the shots, I'm gonna do things my way.

SPEAKER_00Yeah, I know that's it, that's a good question. And I guess to some degree, wherever I've worked, I've always wanted to add value, even as a medic in my NHS years. And then coming into industry was very much a sort of learning curve. And obviously, you have the first role you have is you pretty much signing off materials, MLL, copy review. And that was 17 years ago the mainstay of medical work. But as healthcare systems got more complex, as reimbursement got more complex and medicines got more complex, clearly the role of medical was also evolving. And I've certainly always, even at a junior level, always tried to partner up with my cross-functional people.

SPEAKER_00Sometimes there's a bit of rub. I'm not sure there are people who remember me back in the day. But ultimately, we've all got an opinion on how best to get this medicine into if we again, if we frame it as to we're trying to get these medicines to patients, the right patients. Right. If we're all aligned on that, we're all just going to have a different view as to how that happens. And if we can when you're young in your career, and when I was started out in industry, I didn't always understand actually that whole idea of dynamics and cross-functional collaboration. It was always, it always felt like you're medical and your commercial and your market access. But I think as you navigate through, you realise that the the best outcome is if you're working together on a common objective.

SPEAKER_00You might have different opinions, but as a back to your question, I didn't just wait to become a leader. It was something that I just wanted to be able to do because it's the the nature of wanting to add value. Um I think sometimes it can be hard because there are organizations where um culturally they want to put medical in a particular sort of box. Um, but then that's where I've always thought actually there's more I know I can add to this strategy or medicine or or launch, and I'm going to have those conversations and see if I can convince people at my level.

SPEAKER_00It wasn't always about trying to convince people at a senior level. Um it was working within that team setting.

SPEAKER_01Yeah, and that's it's interesting too, because part of the val I feel like we're saying value a lot. Part of the things that's important about learning how an organization works is forming those relationships with people, right? Where it's like, hey, I know the med legal person, I know his or her perspective on certain things, I know my commercial counterpart, I know this, whether they're super senior, whether they're you just start to know people and their motivations and how to work together.

SPEAKER_01So I'm just wondering, practically speaking, what does this look like for you? Do you have standing cross-department meetings? Are you grabbing people as they're trying to get coffee? Like, how are you managing this?

SPEAKER_00So it's a good question. And again, organization by organization have already different structures set up and meeting set up. And if they don't exist, then I think hopefully medical leaders or people in any function, and not just medical. Again, we're talking about being outside of your bubble. I've certainly seen leaders within organizations from any function realizing actually I need these cross-functional people on board. So I'm going to set up a cross-functional forum, whether it be it might just be like a bi-weekly check-in, or it might be a much more substantive, we need a monthly review on where we are with all things.

SPEAKER_00Um, and that can come from anywhere. And I have seen that come from anywhere. So this again, this is not me trying to say, oh, medical, this is your job to go make this happen. I think if you see that there's a gap, and I've always said this to anyone that I work with from any function, if there's a gap, then there's an opportunity to fill that gap with something that works.

SPEAKER_01And so what would an outcome be from one of these meetings? What are you trying to produce when you're all getting together?

SPEAKER_00I think commonly it's just aligning on what needs to happen for an app for a medicine, right? You've got a medicine, whether it's pre-launch, post-launch, wherever, you've got a particular direction you want to go in, or there's a particular, I don't know, maybe it's a position on a clinical path where you need it to be on. Um, you might have different views on how to get there. There might be different strategies on how to get there. And it is about actually coming together to understand collectively what do we need to do, how do we do it, and then who owns what bit of that bit of the strategy and is empowered then to go forth and do it.

SPEAKER_00So it is about aligning because I think if we're all what can happen is that everyone's working in their own little strands, but not to the same end, and that doesn't help anyone.

SPEAKER_01This episode is sponsored by Structured Meetings. It's a Teams app that turns your own Teams incidents into the perfect advisory board platform. Save money, get insights faster, and keep your data secure. Check it out at www.structuredmeetings.com. No, and uh I'm just curious thinking about that, right? Because a lot of things that again, I often look at things through a technology point of view, because that's the world that I'm I've been in for quite some time.

SPEAKER_01And one of the things that people are often talking about is like trying to connect that information, or somebody you have an ad board and there's an insight, but the MSL who's seeing that doctor doesn't even maybe they don't know that they were invited to the ad board, or maybe they don't know their perspective of that. And maybe it would be really helpful for them to know that for that person it's not actually effectiveness, it's reimburs it's like access that's the core problem for their for their population. So, like have you seen any knowledge approach to viva's our point of truth?

SPEAKER_01We're trying to drive everything in there or whatever the case may be. Is that something that can help probably? I think technology silence.

SPEAKER_00I don't know. I think tech there's still a lot, pharma is still experimenting a lot with tech, and I don't think there's a lot of players in this space. I think in theory, the promise of having one source of truth and being able to understand where we are as an organization at any point and what the strategy is at any point. And then when you're coming down to very granular, which doctor is interested in what at any point, then tech should in theory be able to help us with that. I don't think we're completely there yet. Um, but that's the promise, and I think that's where we will end up.

SPEAKER_00Um, but I'm still to see that joined up in, and I've worked for very big companies. I'm not seeing it completely there yet, is all I'm gonna say.

SPEAKER_01The machines will not save us the time.

SPEAKER_00It is on us, but machines are designed by humans, aren't they? And there's gonna be lots of um and then there's a whole piece around we can have a whole conversation about tech, tech in itself. It's not just the tech itself, it's how what problem is it solving? Have we identified the problems in the first place? How is it gonna solve that problem? How are we then training people so they know how to use the tech properly? How are we integrating it across, you know, organizational structures? It's a lot more complicated. And that's another thing that you probably see me post about on LinkedIn around AI, because everyone thinks they know it.

SPEAKER_00And actually, if you really dig deep, you realize most people don't really even understand the basics, and that's all they want to get at this point in time. How is it gonna help me make my job easier, quicker, faster? But we're not there yet either. I know we've digressed from the metaphairs in in a bubble topic.

SPEAKER_01Um yes, we have, but I I in my mind it's related because it's like AI is a perfect example of a shiny thing that can get people off of that strategy, right? Where uh if two years ago I was at DIA in Boston and there were maybe a couple people talking about AI AI. Last year I was at DIA in San Diego, and every booth, including my own, was like AI this, AI that, right? And people were coming up and saying, I've been tasked with with my company's AI strategy.

SPEAKER_01And I'm like, well, what does that mean? Because what you're talking about before is a strategy to get medicines to patients at pace and at scale. And AI can be at tactic, but it's I don't know that at right now it goes much beyond.

SPEAKER_00No, and I think it's about mapping out what is it going to take to get this medal, what are the barriers, what are the block it, blockages, what are the issues internally, externally, wherever. And then it's about how do we fix those. And if it's an internal issue, is there something AI can help with it comes to process or as we talked about, aligning on certain viewpoints or whatever, insights, all of that sort of thing, data, real world evidence. Similarly, with external barriers, if it are there um are there problems that we can overcome using AI there too? But I think it's about identifying the problem first.

SPEAKER_00I feel like we've putting the cart before the horse a bit. AI is very sexy, it's all over the place. It's a bit like omni-channel. We used to hear about omni-channel like everywhere, and everyone's like, oh, what is all people didn't really understand what omni-channel was. Similarly, it's a tactic, it's a solution to the problem of having consistent messaging or personalized messaging to different groups. Similarly, before then, I'm old enough to remember the buzz around real-world evidence because before it wasn't a thing, and then RWE was everywhere. So I think pharma hops onto these things and then creates a capability around it without really thinking about actually how am I using this?

SPEAKER_00Because ultimately, the whole time I've been in industry, it is ultimately you are making medicines and you're trying to get them to people quickly and to the right people. It's all about the how, I think. And AI can help with that.

SPEAKER_01So in our last few minutes, let's just, if if you'll indulge me, we'll do a little thought exercise, right? So you're living in a perfect world now, right? Where everything is working exactly as it should be, and everybody's talking to each other and everybody's collaborating. What does a day in the life look like for Metafairs and how is that different from how it is now?

SPEAKER_00Oh gosh, that is uh putting me on the spot a bit.

SPEAKER_01Yeah.

SPEAKER_00Again, it it's gonna Okay, so let me think about this. I'm gonna have a bit of time to reflect. What day in the life of perfect, ideal scenario where medical affairs, we're not sitting here constantly defending our value.

SPEAKER_01It's just one well-oiled machine.

SPEAKER_00One well-oiled machine. Okay, so let's give an example where we're launching a medicine in a country. Let's do a country example rather than a global example. Okay, so you've been told by your global teams, okay, we've got this medicine, it's about we're about to file, here's the data. It goes it comes to the country. The general manager's out, okay, team, here we go. This is the medicine, off you go. You've got your in that group, can you've got a cross functional team, you've got your medical lead or your commercial lead, a new market access lead.

SPEAKER_00And obviously, some companies will have different groups. You might have a patient engagement lead, a government affairs lead, whatever. You're all sat around a room, you've got this medicine, you've been tasked with launching it in two years' time, and you've all been given a bit of a role to play. In terms of, okay, here are some things that we don't know about this disease area or whatever, go and get the insights. You've got your government affairs person is going off and understanding the policy landscape. You've got your medical affairs person that's going off, uh getting the insights from clinicians, understanding treatment pathways, guidelines, data gaps, all of that sort of thing.

SPEAKER_00And you've got your payer experts getting the insights from payers and understanding what's needed for reimbursement. How they do that, it's up to them. They might have MSLs, they might have field people, they might have AI, whatever. Um, you then come back together and you'll send your views, thoughts, do a bit of an exercise, map everything out. Who are we? Where are we? What are we trying to do? Who are we trying to engage? How are we going to engage them? What do they need to hear? What are the messages? What data gaps have we got? Where are we trying to put this in the pathway? How are we going to get it there? What evidence do we need to generate? How are we going to generate it?

SPEAKER_00What do payers need to see? What does the government need to see? Any other blockages that we've not thought about? What's happening in the healthcare system today and in the future when we're launching? Um, what do we need to do around the current narrative? Everyone's all in this together, bringing their functional view. We've agreed a plan. We've created various work streams. We've agreed actually, this is what you're going to be owning as medical, this is what you're going to be owning as commercial or marketing, market access, whatever. Off you go.

SPEAKER_00You're empowered to drive your strategic imperatives. And then you just have regular check-in, see how things are going. If there's a problem or there's a you need to pivot, you come together as a team, you agree, and you carry on. And that's how I see things working day to day. And I see that happening till the point of launch. There's always going to be problems and issues, but it is about bringing that team together, everyone collectively inputting and feeling jointly accountable. It's not about your personal, functional, you know, ego. It's about what are we all collectively trying to do, then agreeing that and then owning bits of that puzzle.

SPEAKER_00And that's how I see things working. And I think celebrating successes on the way, recognizing where impact has been made and how it's been made. And for me, that is, I've seen it work like that, and it's beautiful when it works like that. But it does require that sort of strength and courage and leadership to hold people to account to have it work like that. How does that sound to you?

SPEAKER_01That sounds great. All right. And what's really cool about it to me is none, you know, it's not, oh, we need to wait for this or that. There's nothing really blocking that from happening now, other than mindset and organization and culture. And again, it's almost now. I'm sorry to feel guilty about what I said about the company. It's almost the same thing, right? Where it's like people aren't operating in, let's say, non-ideal ways because they're bad at their job or anything like that, right? It's there are various pressures and various responsibilities that they're focused at all the time.

SPEAKER_01Where it's I'll give you an example for my career, like I was trying to get some outside professional training skills development for my team. And I was really faced by manage like resistance from management. Hey, this is a great idea, but now's not the time. We really need to, we really need to hit our quarter, we really need to do this, that, or the other thing. And it's there's always going that that is not going to go away at the end of the year or at the end of the quarter, right? Those other pressures are always going to be there. So at some point, you just have to carve it out and say, no, we believe this is important and we're going to develop our people and we're going to work the way we want to work.

SPEAKER_00Yeah. And but I think there's it's so complicated. What we've described is an ideal world. I've the world isn't ideal. Lots of things get in the way. There's going to be, and I'm going again talking about more broadly, there's personal ego, there's personal career, there are people that are trying to prove themselves, and there's all sorts of things that can get in the way of that ideal scenario, as well as organizational pressure and cultural pressures and all that sort of thing. But for me, I think the key thing is for any function, and particularly in medical affairs, and I know that medical affairs have tried to reinvent themselves, and that's perhaps why we're talking to each other quite a lot, because actually, maybe a lot of it is a bit of a sort of supportive role and encouraging each other to have faith.

SPEAKER_00But at some point, we've got to encourage medical affairs to really think about their role in the broader spectrum. It's not just all about medical affairs. I don't know how many posts I see on LinkedIn. It might just be the algorithm. Maybe that's what it needs to be. I just need to change, sort of sort the algorithm out. Where it's about the value medical can bring and field medical excellence and MSL's this. And I don't know. I just I sometimes feel like it's a bit too much. And I don't know whether that's reality because if you go into an organization, it's not just medical sat here trying to say, oh, you know, we're very important.

SPEAKER_00It is a it's a the where it works, it is about that cross-functional collaboration. The organizations get it, they encourage it, and it's happening and it works well.

SPEAKER_01Right. Just be important and you won't have to tell people you're important.

SPEAKER_00Yeah, that's a good message. Be important. So I don't know. I'd love to get your thoughts on it. Do you think I was off the mark? I know you felt personally a bit attacked with by my stop talking together in a bubble. But things like maps, that's a great organization, great place for medical to connect, but it is all medical. And I'm like sometimes going there, going, actually, where's the commercial voice?

SPEAKER_01That's a really interesting point, right? It would be very cool to see, you know, a commercial, a clinical speaker, even one or two throughout the day at MAPS talking about how we can collaborate. And again, it's not just medical affairs. Again, the this regulatory symposium is a great example where the FDA was in the room. Like there's a lot of deep thinkers about this stuff, but there was nobody from other organizations there. Yeah. Because it's again, it's just viewed as that's that's your job. You like there's these silos. So, from my perspective, this is a good place to end the conversation.

SPEAKER_01Excellent. So thank you, Dr. Simeen Saad. I really appreciate your time today.

SPEAKER_00You're welcome. Thank you for having me.

SPEAKER_01This episode is sponsored by Structured Meetings. For listeners who don't know my background, I'm a huge fan of asynchronous adboards. I used to work for the leading provider of async adboards, and, not to brag, but my clients did more events than anyone else's. I've literally led thousands from the vendor side, so I can humbly claim some expertise. One of the questions I used to get all the time was, can we just do this in Teams? And the answer back then was, not really. Teams out of the box is clunky and not fit for purpose. Structured meetings change that by creating an MS Teams app that lets you have these discussions in a really smart way in your own Teams instance.

SPEAKER_01It changes Teams just enough to check all the boxes for what's needed for great ad boards. And also, it's super fast and it saves people a ton of money. Visit www.structuredmeetings.com for more info. All right, back to the show.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Built to Move: Candel Therapeutics' Agile Path from Trial Results to Launch Readiness

    Nov 4, 202636 minAudio

    Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, sits down with Jonathan to discuss the company's sprint from positive Phase III results to commercial launch. They explore how Candel is redefining the...

    Credit the people on this episode

  2. Data, AI, and the Future of Field Training with Annel Duckels from BMS

    Sep 24, 202617 minAudio

    In this episode, Jonathan sits down with Annel Duckels, who leads worldwide commercialization learning at Bristol Myers Squibb, to talk about modernizing pharma training through data and AI. Annel's unconventional path...

    Credit the people on this episode

  3. Hallway Interviews with Pharma Learning Leaders

    Jul 31, 202639 minAudio

    Pharma Sessions - ACTO Client Summit: Hallway Interviews At ACTO's 2026 client summit in Boston, we pulled some incredible minds out of the hallway for quick, candid conversations about where field excellence, AI, and...

    Credit the people on this episode

  4. Blockchain + AI: The Future of Healthcare Data

    Jul 9, 202633 minAudio

    What happens when you put blockchain underneath AI in healthcare? According to Archita Samant, Head of Data Strategy & Analytics for Global Vaccines at Merck - you finally solve the interoperability problem that's been...

    Credit the people on this episode

  5. The Question Behind the Question - Field Training with Jennifer Muszik

    Jun 8, 202629 minAudio

    What separates a good pharma sales rep from a great one? According to Jennifer Muszik, it's the ability to understand the question behind the question - the real need behind what a customer is asking. In this episode,...

    Credit the people on this episode